On-chip 3D potency assay for prediction of clinical outcomes for cell therapy candidates for osteoarthritis

Rebecca S. Schneider, Elisa B. Nieves, Bhavay Aggarwal, Annie C. Bowles-Welch, Hazel Y. Stevens, Linda E. Kippner, Scott D. Boden, Kenneth Mautner, Hicham Drissi, Krishnendu Roy, Wilbur A. Lam, Saurabh Sinha and Andrés J. García ()
Additional contact information
Rebecca S. Schneider: Georgia Institute of Technology
Elisa B. Nieves: Georgia Institute of Technology
Bhavay Aggarwal: Georgia Institute of Technology and Emory University
Annie C. Bowles-Welch: Georgia Institute of Technology
Hazel Y. Stevens: Georgia Institute of Technology
Linda E. Kippner: Georgia Institute of Technology
Scott D. Boden: Emory University
Kenneth Mautner: Emory University
Hicham Drissi: Emory University
Krishnendu Roy: Georgia Institute of Technology
Wilbur A. Lam: Georgia Institute of Technology
Saurabh Sinha: Georgia Institute of Technology and Emory University
Andrés J. García: Georgia Institute of Technology

Nature Communications, 2025, vol. 16, issue 1, 1-12

Abstract: Abstract The lack of clinically predictive potency assays for cell products significantly impedes translation of these therapies. Here, we describe a microfluidic on-chip 3D system for rapid evaluation of a subset of patient-derived bone marrow aspirate concentrate (BMAC) samples used in a phase 3 multicenter trial (NCT03818737) evaluating autologous cells for relieving knee osteoarthritis pain. BMAC clinical samples cultured in the on-chip 3D system exhibit elevated levels of immunomodulatory and trophic proteins compared to 2D culture. Using analyte information from in vitro assays and patient-matched clinical data, we build linear regression prediction models for clinical outcomes. We demonstrate improved clinical prediction by cross-validation accuracy for the on-chip 3D platform compared to 2D culture. Additionally, on-chip 3D assay metrics display higher correlative power with patient pain scores compared to the 2D assay. This study establishes a potency assay with improved prediction power to accelerate translation of cell therapies.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-60158-w Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-60158-w

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-60158-w

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().